+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Hyperphosphatemia Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767741
  • Report
  • April 2019
  • Region: Global
  • 221 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Ardelyx Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Galenica Ltd
  • Sanofi
  • MORE
The global clinical trial report- “2019 Hyperphosphatemia Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Hyperphosphatemia. It presents in-depth analysis of Hyperphosphatemia clinical trials across markets and companies. The research work is for providing complete understanding into trends in Hyperphosphatemia.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Hyperphosphatemia clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Hyperphosphatemia

The research work is prepared through extensive and continuous research on Hyperphosphatemia trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Hyperphosphatemia patients are identified
  • The report includes panorama of Hyperphosphatemia clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Hyperphosphatemia clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ardelyx Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Galenica Ltd
  • Sanofi
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Hyperphosphatemia Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Hyperphosphatemia Clinical Trials by Region
2.2.2 Average Enrollment of Hyperphosphatemia Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Hyperphosphatemia Treatment, 2019

3. Region wise Hyperphosphatemia Clinical Trials
3.1 Asia Pacific Hyperphosphatemia Clinical Trials by Country
3.2 Europe Hyperphosphatemia Clinical Trials by Country
3.3 North America Hyperphosphatemia Clinical Trials by Country
3.4 Middle East and Africa Hyperphosphatemia Clinical Trials by Country
3.5 South and Central America Hyperphosphatemia Clinical Trials by Country

4. Hyperphosphatemia Clinical Trial Trends
4.1 Start Year wise Hyperphosphatemia Clinical Trials
4.2 Phase wise Hyperphosphatemia Clinical Trials
4.3 Trial Status wise Hyperphosphatemia Clinical Trials
4.4 Trial Type wise Hyperphosphatemia Clinical Trials

5. Hyperphosphatemia Average Enrollment Trends
5.1 Average Enrollment in Hyperphosphatemia Trials by Year
5.2 Average Enrollment in Hyperphosphatemia Trials by Phase
5.3 Average Enrollment in Hyperphosphatemia Trials by Status
5.4 Average Enrollment in Hyperphosphatemia Trials by Type of Trial

6. Companies Participating in Hyperphosphatemia Clinical Trials
6.1 Hyperphosphatemia Trials by Sponsor Type
6.2 Hyperphosphatemia Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Hyperphosphatemia Trials- Phase 1
7.2 Hyperphosphatemia Trials- Phase 2
7.3 Hyperphosphatemia Trials- Phase 3
7.4 Hyperphosphatemia Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Hyperphosphatemia Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Figure 5: Europe - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Figure 7: North America - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Figure 9: Hyperphosphatemia Clinical Trials by Phase
Figure 10: Hyperphosphatemia Clinical Trials by Trial Status
Figure 11: Hyperphosphatemia Clinical Trials by Type
Figure 12: Hyperphosphatemia Clinical Trials by Sponsor Type
Figure 13: Hyperphosphatemia Clinical Trials by Leading Sponsors
Figure 14: Hyperphosphatemia Average Enrollment by Phase
Figure 15: Hyperphosphatemia Average Enrollment by Trial Status
Figure 16: Hyperphosphatemia Average Enrollment by Type
Figure 17: Hyperphosphatemia- Average Enrolment by Type of Sponsors
Figure 18: Hyperphosphatemia- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Hyperphosphatemia Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Table 5: Europe - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Table 7: North America - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Hyperphosphatemia Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Hyperphosphatemia Average Enrollment by Phase
Table 15: Hyperphosphatemia Average Enrollment by Trial Status
Table 16: Hyperphosphatemia Average Enrollment by Type
Table 17: Hyperphosphatemia- Average Enrolment by Type of Sponsors
Table 18: Hyperphosphatemia- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3
  • Ardelyx Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Galenica Ltd
  • Keryx Biopharmaceuticals Inc
  • Kissei Pharmaceutical Co Ltd
  • Mitsubishi Chemical Holdings Corp
  • Sanofi
  • Shire Plc
Note: Product cover images may vary from those shown
Adroll
adroll